15.12
対数線形モデルは、薬物濃度と効果の関係を記述するために用いられる薬力学的モデルです。このモデルは、観察される効果が薬物の最大効果(E_max)の20%から80%の範囲にある場合に特に有用であり、この範囲では薬物濃度の対数と観測された効果との間にほぼ直線的な関係が認められます。しかし、対数線形モデルは…
対数線形モデルは、効果が薬物濃度の対数に比例すると仮定します。
効果Eは次の式で与えられます。ここで、Sは単位薬物濃度によって生じる効果を表し、Cは血漿薬物濃度、E0は基準効果を示します。
最大効果であるEmaxが20%から80%の間にある場合、薬物濃度と効果の対数のプロットはほぼ線形に見えます。
特筆すべきは、このモデルは薬物濃度ゼロ時のEmaxや効果を予測できないことです。
しかし、ワルファリンやプロプラノロールなどの薬剤の濃度-効果関係を予測するためにも用いられます。
例えば、プロプラノロールの血漿濃度のログと運動誘発性頻脈の割合ブロックのプロットは、静脈経路および経口経路の両方で線形です。
その結果、プロプラノロール濃度を上げることで運動誘発性頻脈が効果的に減少し、静脈経路の方がより顕著で一貫した反応を示します。
View the full transcript and gain access to JoVE Core videos
Q1: What is the log-linear model in pharmacodynamics?
The log-linear model describes the relationship between drug concentration and its effect by assuming the effect is directly proportional to the logarithm of drug concentration. It uses the equation E = S × log(C) + E0, where S represents the effect per unit concentration, C is plasma drug concentration, and E0 is baseline effect. This model is particularly useful when drug effects range between 20% and 80% of maximum effect.
Q2: When is the log-linear model most applicable in drug analysis?
The log-linear model is most applicable when observed drug effects fall between 20% and 80% of the maximum effect (Emax), where the relationship between log drug concentration and effect appears nearly linear. Within this range, the model accurately predicts concentration-effect relationships for drugs like warfarin and propranolol, making it valuable for understanding pharmacodynamic responses in clinical settings.
Q3: What are the limitations of the log-linear pharmacodynamic model?
The log-linear model cannot predict the maximum possible effect (Emax) or the effect at zero drug concentration, limiting its applicability in complete pharmacodynamic analyses. These limitations mean the model is restricted to predicting concentration-effect relationships within the linear range and cannot extrapolate to extreme effect values or baseline conditions.
Q4: How does propranolol concentration affect exercise-induced tachycardia?
Propranolol demonstrates a linear concentration-effect relationship with exercise-induced tachycardia when plotted on a logarithmic scale. Increasing propranolol concentration effectively reduces tachycardia by blocking β-adrenergic receptors. The intravenous route produces more pronounced and consistent responses compared to oral administration due to reduced variability in bioavailability and plasma concentration.
Q5: Why does intravenous propranolol show a more consistent response than oral administration?
Intravenous propranolol administration produces more consistent and pronounced responses because it avoids the variability associated with oral bioavailability and absorption. IV administration results in more predictable plasma concentrations, allowing the log-linear model to accurately describe the concentration-effect relationship. Oral routes introduce additional variables that reduce response consistency.
Q6: Which drugs are effectively modeled using the log-linear concentration-effect approach?
Warfarin and propranolol are primary examples of drugs effectively modeled using the log-linear approach. Both drugs demonstrate linear relationships between log plasma concentration and their pharmacological effects within the 20-80% Emax range. This makes the log-linear model particularly valuable for predicting and understanding the concentration-effect relationships of these commonly used medications.
Q7: How does the log-linear model differ from other pharmacodynamic models?
The log-linear model assumes a linear relationship between log drug concentration and effect, differing from models that describe sigmoidal or non-linear relationships. Unlike the Emax model, the log-linear model cannot predict maximum effect or baseline response. It is specifically designed for the middle range of drug effects and provides a simplified approach to concentration-effect prediction within defined boundaries.